PRO-LISINOPRIL - 5 TABLET

Pajjiż: Kanada

Lingwa: Ingliż

Sors: Health Canada

Ingredjent attiv:

LISINOPRIL

Disponibbli minn:

PRO DOC LIMITEE

Kodiċi ATC:

C09AA03

INN (Isem Internazzjonali):

LISINOPRIL

Dożaġġ:

5MG

Għamla farmaċewtika:

TABLET

Kompożizzjoni:

LISINOPRIL 5MG

Rotta amministrattiva:

ORAL

Unitajiet fil-pakkett:

100/500

Tip ta 'preskrizzjoni:

Prescription

Żona terapewtika:

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS

Sommarju tal-prodott:

Active ingredient group (AIG) number: 0121550003; AHFS:

L-istatus ta 'awtorizzazzjoni:

APPROVED

Data ta 'l-awtorizzazzjoni:

2008-06-12

Karatteristiċi tal-prodott

1 | P a g e
1
PRODUCT MONOGRAPH
PR
PRO-LISINOPRIL – 5
PR
PRO-LISINOPRIL – 10
PR
PRO-LISINOPRIL – 20
(LISINOPRIL TABLETS USP)
TABLETS 5 MG, 10 MG AND 20 MG
ANGIOTENSIN CONVERTING ENZYME INHIBITOR
DATE OF REVISION:
MARCH 14, 2022
PRO DOC LTÉE
2925, BOUL. INDUSTRIEL
LAVAL, QUÉBEC
H7L 3W9
_Submission Control No.:_
_261621_
2 | P a g e
PRODUCT MONOGRAPH
Pr
PRO-LISINOPRIL – 5
Pr
PRO-LISINOPRIL – 10
Pr
PRO-LISINOPRIL – 20
(Lisinopril Tablets USP)
Tablets 5 mg, 10 mg and 20 mg
Angiotensin Converting Enzyme Inhibitor
ACTIONS AND CLINICAL PHARMACOLOGY
Lisinopril is an angiotensin converting enzyme (ACE) inhibitor which
is used in the treatment of
hypertension, congestive heart failure and following myocardial
infarction in hemodynamically
stable patients.
ACE is a peptidyl dipeptidase which catalyzes the conversion of
angiotensin I to the pressor
substance, angiotensin II. Inhibition of ACE results in decreased
plasma angiotensin II, which
leads to increased plasma renin activity (due to removal of negative
feedback of renin release)
and decreased aldosterone secretion. Although the latter decrease is
small, it results in a small
increase in serum potassium. In patients treated with lisinopril and a
thiazide diuretic there was
essentially no change in serum potassium (see PRECAUTIONS).
ACE is identical to kininase II. Thus, lisinopril may also block the
degradation of bradykinin, a
potent vasodilator peptide. However, the role that this plays in the
therapeutic effects of lisinopril
is unknown.
While the mechanism through which lisinopril lowers blood pressure is
believed to be primarily
the suppression of the renin-angiotensin-aldosterone system (RAAS),
lisinopril also lowers blood
pressure in patients with low-renin hypertension.
PHARMACODYNAMICS
Hypertension
_Adults:_ Administration of lisinopril to patients with hypertension
results in a reduction of both
supine and standing blood pressure. Abrupt withdrawal of lisinopril
has not been associated with
a rapid increase in blood pressure. In most patients st